Comparison · NCT00234065-9e6dc2a7
Cilostazol vs Aspirin: Numbers of Patients With First Occurence of Stroke
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cilostazol vs Aspirin: Numbers of Patients With First Occurence of Stroke. Trial comparisons, record NCT00234065-9e6dc2a7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00234065-9e6dc2a7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0613 | 0.0497 | 0.0755 | wilson | |
| Risk in group 2 | 0.0891 | 0.075 | 0.106 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0278 | -0.048 | -0.0078 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.688 | 0.525 | 0.902 | log | |
| Odds ratio, group 1 over group 2 | 0.668 | 0.499 | 0.894 | log | |
| Number needed to treat, for one fewer participant with the outcome on Cilostazol than on Aspirin | 36 | 20.8 | 128 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cilostazol | cilostazol, oral tablet, 100 mg cilostazol | 82 | 1,337 | OG000 |
| Group 2 | Aspirin | Aspirin, oral tablet, 81 mg aspirin | 119 | 1,335 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Numbers of Patients With First Occurence of Stroke
- Description
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
- Time frame
- From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])
- Population
Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.
Source ClinicalTrials.gov
Trial
- Title
- Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
- NCT number
- NCT00234065
- Phases
- PHASE4
- Conditions
- Cerebral Infarction
- Interventions
- Cilostazol, Aspirin
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Results first posted
- 2011-05-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00234065?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00234065-9e6dc2a7